These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 19417638

  • 1. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
    Pedersen ME, Cockcroft JR.
    Curr Opin Cardiol; 2009 Jul; 24(4):325-32. PubMed ID: 19417638
    [Abstract] [Full Text] [Related]

  • 2. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J, Barbosa L, Silva JA, Bertoquini S.
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [Abstract] [Full Text] [Related]

  • 3. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H, Lavie CJ, Ventura HO.
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [Abstract] [Full Text] [Related]

  • 4. The vasodilatory beta-blockers.
    Pedersen ME, Cockcroft JR.
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [Abstract] [Full Text] [Related]

  • 5. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G.
    J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
    [Abstract] [Full Text] [Related]

  • 6. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.
    Bakris GL, Basile JN, Giles TD, Taylor AA.
    Am J Med; 2010 Jul; 123(7 Suppl 1):S2-8. PubMed ID: 20609695
    [Abstract] [Full Text] [Related]

  • 7. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking.
    Vyssoulis GP, Marinakis AG, Aznaouridis KA, Karpanou EA, Arapogianni AN, Cokkinos DV, Stefanadis CI.
    Am J Hypertens; 2004 Jul; 17(7):582-9. PubMed ID: 15233977
    [Abstract] [Full Text] [Related]

  • 8. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 9. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A, Feely J.
    Am J Hypertens; 2008 Jun; 21(6):663-7. PubMed ID: 18437130
    [Abstract] [Full Text] [Related]

  • 10. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N, Lim PO, MacDonald TM.
    Circulation; 2001 Jul 31; 104(5):511-4. PubMed ID: 11479245
    [Abstract] [Full Text] [Related]

  • 11. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
    Drugs; 2010 Jul 31; 70(1):41-56. PubMed ID: 20030424
    [Abstract] [Full Text] [Related]

  • 12. Beta-blockers for hypertension: are they going out of style?
    Che Q, Schreiber MJ, Rafey MA.
    Cleve Clin J Med; 2009 Sep 31; 76(9):533-42. PubMed ID: 19726558
    [Abstract] [Full Text] [Related]

  • 13. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
    Black HR, Greenberg BH, Weber MA.
    Am J Med; 2010 Nov 31; 123(11):S2. PubMed ID: 21035578
    [Abstract] [Full Text] [Related]

  • 14. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr 31; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

  • 15. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 31; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 16. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug 31; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

  • 17. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov 31; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 18. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E, Rizzoni D.
    Drugs; 2007 Nov 31; 67(8):1097-107. PubMed ID: 17521213
    [Abstract] [Full Text] [Related]

  • 19. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL, Saseen JJ.
    Ann Pharmacother; 2014 Jun 31; 48(6):723-33. PubMed ID: 24687542
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
    Buval'tsev VI, Spasskaia MB, Nebieridze DV, Metel'skaia VA, Guseva OI.
    Klin Med (Mosk); 2003 Jun 31; 81(7):51-5. PubMed ID: 12934313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.